1 week Ago By Defense World Staff
Shares of Pharming Group (NASDAQ:PHAR – Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $8.09, but opened at $7.
79. Pharming Group shares last traded at $7.85, with a volume of 677 shares.
Analyst Ratings ChangesA number of research firms have weighed in on PHAR. Oppenheimer upped their price objective on shares of Pharming Group from $30.00 to $39.
00 and gave the company an “outperform” rating in a research report on Friday, March 14th. HC Wainwright restated a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research note on Thursday, March 20th.
Get Our Latest Stock Analysis on Pharming GroupPharming Group Stock PerformanceThe company has a market capitalization of $547.65 million, a price-to-earnings ratio of -30.96 and a beta of -0.
08. The company’s fifty day simple moving average is $8.57 and its two-hundred day simple moving average is $8.
70. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.
76 and a current ratio of 3.53. Pharming Group (NASDAQ:PHAR – Get Free Report) last announced its quarterly earnings data on Thursday, March 13th.
The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.
02). Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.
65%. The firm had revenue of $92.70 million during the quarter, compared to the consensus estimate of $76.
67 million. Equities research analysts predict that Pharming Group will post -0.2 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Pharming GroupAn institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its stake in shares of Pharming Group (NASDAQ:PHAR – Free Report) by 16.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).
The firm owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period.
Institutional investors own 0.03% of the company’s stock. About Pharming Group (Get Free Report)Pharming Group N.
V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read MoreFive stocks we like better than Pharming GroupTop Biotech Stocks: Exploring Innovation OpportunitiesRobinhood Strategies Could Be a Game-Changer for Young InvestorsConference Calls and Individual InvestorsAre These 3 Retail Stocks Oversold or Really in Trouble?Golden Cross Stocks: Pattern, Examples and Charts IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead.
